- Products & Services
- Knowledge Base
WESTLAKE VILLAGE, CA, September 03, 2019 /24-7PressRelease/ -- Rx-Precision is a two-year-old startup that solves the medication management problem common with high- risk, high-cost patients by using a new care delivery model to tailor their medications to their DNA (a science called Pharmacogenomics).
Their AI-driven solution called PGx-Guided Care proactively identifies patients in an employer or health plan population who will clinically benefit from Pharmacogenomics testing and lead to lower costs, and then guides the patient and their physician through the entire testing and medication optimization process.
Rx-Precision makes money by contracting with large employers and health plans for the service and the health plans benefit from improved member outcomes and lower pharmacy and medical costs.
The OCMX™ is pleased to announce the listing of Rx-Precision, Inc. to its online portal which offers Investors and Advisors the ability to participate in this opportunity.
The OCMX™ has spent considerable time completing its due diligence on Rx-Precision, Inc. and concluded that there is indeed a tremendous opportunity for Investors and Advisors.
The OCMX™ noted that Rx-Precision, Inc. exhibits the main components of any solid investment opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.
Dean Sawyer, MBA, Chief Executive Officer
Dean is a healthcare industry veteran and digital health pioneer with more than twenty years of hands-on digital health experience as a startup Founder, CEO, Chief Commercial Officer and VP of Sales. Dean also has experience as a Partner and Advisor for venture capital firms and startup incubators, accelerators and growth foundries.
Dean has developed and commercialized a number of dynamic and disruptive systems to advance the healthcare industry including products in the Remote Patient Monitoring, Medical Device, Artificial Intelligence, Electronic Health Record and Enterprise Software space.
Notable roles include Founder and CEO of Sentrian, a venture-backed remote patient monitoring and AI company focused on eliminating preventable hospitalizations in patients with complex chronic disease, Vice President of Sales at the early-stage EHR company, Allscripts where he helped grown annual revenue from zero to $180 million, Chief Revenue Officer at Aptus Health where he grew sales from $1 million to $32 million and was instrumental in the commercialization of one of the first mobile decision support tools for medical professionals and one of the first digital sales channels in the pharmaceutical industry.
Dean earned an MBA from Pepperdine University, holds a B.S. in Business Administration from the University of the Pacific and completed the Exponential Medicine Program at Singularity University.
Jake Velie, Founder & Chief Strategy Officer
Jake has owned and operated family medicine, integrated health, and behavioral health clinics where he saw first hand how clinical solutions and advancements based on precision medicine can change the way we treat disease.
Jake also has nearly 20 years of experience as a trusted consultant to physician groups, health systems, health plans, self-insured employers and third-party administrators. Jake consults in the areas of population health, precision medicine, data analytics/AI and healthcare information technology.
Jake is also the Clinical Advisory Board Chairman of National Integrative Health (NIH) where he helps develop genomic, medication therapy management, behavioral health and other precision management clinical improvement strategies for employers and health systems.
Jake also provides expert content in more than 300 radio markets across the country in various syndicated radio segments.
Roni Amiel, Chief Technology Officer
Roni has more 20 years of industry healthcare technology experience in roles as CTO, CIO and CISO at Health Systems, Pharmaceutical, Biotechnology, Payer, Academic, City/State Government and Medical device companies.
Before joining Rx-Precision, Roni was the CIO and CISO at Notal Vision where he developed a best-in-class, cloud- based platform to effectively and efficiently address large unmet diagnostic, economic, and social needs in ophthalmology. Prior to that he was a Co-Founder and CTO of Pinscriptive, where he built an advanced analytics decision support cloud platform in the specialty pharmaceutical and pharmacogenomics space. He was also the CIO/CISO for the office of the Chief Medical Examiner of the City of New York's Department of Health where he spearheaded the development of a cloud-based DNA analytics platform for the largest Lab in the country.
Roni holds an MS in Biomedical Informatics and has completed academic programs in Information Technology, Business Strategy, Executive Leadership, Project Management, and Finance from NYU and Colorado Technical University. Mr. Amiel has 4 Patents in the Treatment decision, Decision support and Forecasting treatment decision in healthcare systems.
Martin S. Kohn, MD, MS, FACEP, FACPE
Dr. Martin Kohn is an expert in health data analytics, health policy and healthcare management. He is an experienced physician, clinical informaticist, and health policy analyst. He was most recently Chief Medical Scientist at Sentrian, which creates predictive analytic systems integrating home monitoring with longitudinal health data for patients with complex chronic diseases. Sentrian identifies patients who are likely to need hospitalization days before they become seriously ill to provide time to intervene and avoid hospitalization. Previously, he was the Chief Medical Scientist for Care Delivery Systems in IBM Research developing analytic tools for healthcare, including the use of the Watson supercomputer.
Dr. Kohn is a board-certified emergency medicine physician with over 30 years of practice and management experience and is Adjunct Clinical Faculty in the Clinical and Translational Science Institute at the Wake Forest School of Medicine. He received bachelor and master of science degrees in electrical engineering from MIT, a MD from Harvard Medical School and a master's degree in health management and policy from NYU. He did additional graduate study in bio-medical engineering at Stanford. He has been a healthcare executive, educator and congressional health policy advisor. Dr. Kohn is board certified in Clinical Informatics, a certified physician executive and has published on clinical, technical, management and policy subjects.
He speaks frequently on the role of "Big Data" and artificial intelligence in clinical decision support and the transformation of healthcare. His broad background and publications in engineering, data science, clinical medicine, management and health policy allow him to work closely with all healthcare stakeholders in the joint effort of technology in healthcare.
Joshua Ridgeway, Co-Founder & Chief Operating Officer
As COO, Joshua designed, built and manages our case management operations which includes member enrollment, testing and all activities between the lab, member, genetic counselors and treating physicians.
Prior to Rx-Precision, Joshua was the CEO of GreenRidge Plastics, the Strategic Planning Manager for Budmark Oil and ran operations of a number of family-owned businesses.
Joshua's expertise is in implementing and improving cost-effective operation workflows, operational controls, administration and reporting procedures and developing vendor partnerships to grow and scale operations.
Josh has a Bachelor's Degree in Marketing from Florida State University College of Business.
Shital Patel, Chief Financial Officer
As Chief Financial Officer, Shital is responsible for all of the company's financial functions including accounting,audit, treasury, corporate finance and investor relations. Shital also leads human resource and legal activities.
Her career spans more than 15 years of varied experience in financial management, business leadership and corporate strategy for software companies. Prior to joining Rx-Precision, Shital held previous CFO and Management positions at Pivotus Ventures, Maana and Microsoft.
Shital earned a Bachelors of Speech Communication from California State University of Fullerton.
ABOUT THE OCMX™
The OCMX™ is literally changing how companies and investment funds generate exposure in the marketplace and raise funds as we know it. The OCMX™ serves both public and private companies along with investment and mutual funds which need to raise additional funds or gain significant market exposure. It does this by way of connecting the relevant companies, funds, investors, and advisors all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.
The OCMX™ connects investors and advisors directly with companies and investment funds seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors.
The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.
TD Canada Trust Tower 161 Bay Street, 45th Floor Toronto, Ontario, M5J 2S1 Tel: 1-866-209-6862
# # #